82P Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistently strong operating and free cash flow provides durable financial flexibility: funds R&D, funds the PCRX-201 program, supports debt paydown (noted use of divestiture proceeds), and cushions the company against procedure-volume cyclicality over the next 2–6 months.
Improving Balance-sheet And LeverageReduced leverage and a sizable equity base lower refinancing and solvency risk, enabling Pacira to fund clinical programs and commercialization without urgent external financing, supporting operational resilience and strategic flexibility over the medium term.
Major Payer Wins / Market AccessExpanded payer coverage materially increases addressable patient access for EXPAREL and ZILRETTA, reducing barriers to adoption in hospitals and outpatient sites and creating a structural commercial tailwind that supports sustained volume growth and pricing leverage over months.
Bears Say
Gross Margin CompressionA multi-point decline in gross margin signals pressure from product mix shifts, inventory cost timing, and discounting; persistent margin erosion would reduce cash per dollar of sales and constrain reinvestment capacity even if revenues grow modestly.
Earnings VolatilityLarge year-to-year swings in profitability make forward earnings less predictable, complicating multi-quarter planning for R&D, commercial spend, and capital allocation; continued volatility could pressure credit metrics despite solid cash flow.
Reimbursement And Procedure ExposureMeaningful reliance on CMS policy and elective procedure volumes creates structural demand risk: an adverse CMS decision or prolonged softness in inpatient procedures would materially reduce EXPAREL use and revenue visibility over the next 12–18 months.
Pacira Pharmaceuticals News
82P FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is CHF790.38M.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 78 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Aug 04, 2026. The company reported CHF0.59 earnings per share for the quarter, beating the consensus estimate of CHF0.522 by CHF0.068.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.6.
How many shares outstanding does Pacira Pharmaceuticals have?
Currently, no data Available
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of CHF0.59 in its last earnings report, beating expectations of CHF0.522. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:82P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF23.29 (― Upside)
CHF23.29 (― Upside)
Blogger Sentiment
Bullish
CH:82P Sentiment 67%
Sector Average 62%
Sector Average 62%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.08%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
82P Company Deck
82P Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted solid financial performance (6% revenue growth, robust adjusted EBITDA, strong cash position), meaningful commercial progress (major payer wins covering ~150M lives, EXPAREL and ZILRETTA momentum), important pipeline and manufacturing milestones (PCRX-201 manufacturing, multiple imminent readouts), and a strategic portfolio move (iovera divestiture with up to $140M consideration). Key challenges include softness in elective inpatient soft tissue procedures driven by macroeconomic factors, a decline in gross margin versus prior year, higher R&D and SG&A spend, and modest near-term moderation in EXPAREL volume growth. Overall, the positives — including clear payer wins, pipeline catalysts, cash generation, and strategic partnerships — outweigh the operational and margin headwinds.View all CH:82P earnings summaries82P Stock 12 Month Forecast
Average Price Target
―Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―